Stock listing

8AK Stock Price, News, Filings & Events — Alkermes Plc

Selected listing: 8AK · SWB · EUR · DE

This page tracks Alkermes Plc's 8AK:SWB listing on SWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 8AK:SWB. 8AK:SWB is the stock-level entry point for investors researching Alkermes Plc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Alkermes Plc (Ticker: ALKS) is a public company based in America, with a market capitalization of approximately $8.82 billion. The company focuses on developing innovative medicines for patients with serious mental health conditions and addiction. Alkermes is committed to improving patient outcomes through its research and development efforts.

8AK:SWBEURDEUpdated August 28, 2026
Alkermes Plc logo
Ticker
8AK:SWB
Asset type
Stock
Market cap
$7.95B
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
SWB
Currency
EUR

Alkermes Plc 8AK:SWB stock context

This page tracks Alkermes Plc's 8AK:SWB listing on SWB in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 8AK:SWB. 8AK:SWB is the stock-level entry point for investors researching Alkermes Plc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Alkermes Plc (Ticker: ALKS) is a public company based in America, with a market capitalization of approximately $8.82 billion. The company focuses on developing innovative medicines for patients with serious mental health conditions and addiction. Alkermes is committed to improving patient outcomes through its research and development efforts.

Latest news from Alkermes Plc

All Alkermes Plc news →

Alkermes Plc earnings calls

Research Alkermes Plc

Alternate listings